Patents Examined by James D. Schultz
-
Patent number: 12129490Abstract: Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.Type: GrantFiled: August 22, 2018Date of Patent: October 29, 2024Assignees: UNIVERSITY HEALTH NETWORK, THE HOSPITAL FOR SICK CHILDRENInventors: Gordon Keller, Shinichiro Ogawa, Anand Ghanekar, Christine Bear, Binita M. Kamath, Mina Ogawa, James Surapisitchat
-
Patent number: 12083189Abstract: Tail-tail RNA conjugates translatable by eukaryotic ribosomes, and pharmaceutically acceptable compositions including the same are provided. Methods for preparing such molecules, using them for treating and preventing diseases are described. In addition, processes for producing desired polypeptides using the molecules are also described.Type: GrantFiled: April 27, 2023Date of Patent: September 10, 2024Assignee: TIBA BIOTECH, LLCInventors: Jasdave S Chahal, Justine S McPartlan
-
Patent number: 12060394Abstract: Nucleic acid constructs, vectors, and recombinant cells harboring the nucleic acid constructs or vectors are disclosed. The nucleic acid constructs include genes encoding a chimeric antigen receptor (CAR) and/or one or more transcription factors, optionally mutated. The transcription factors include those that mediate proinflammatory cytokine expression, e.g., T-bet, STAT1, or STAT4. Methods are disclosed of co-expression of the CAR and the transcription factor in a human or non-human immune cell, preferably human T cells. Also disclosed are methods for using these cells for immunotherapy, e.g., in treating cancer, infection, autoimmunity, allergy or inflammation diseases by the administration of a prophylactically or therapeutically effective amount of one or more of the nucleic acid constructs, vectors, and/or immune cells, e.g., human CAR-T cells, described herein.Type: GrantFiled: April 28, 2017Date of Patent: August 13, 2024Assignee: THE TRUSTEES OF DARTMOUTH COLLEGEInventors: Charles L. Sentman, Albert Gacerez
-
Patent number: 12043673Abstract: The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides. Two antibodies are capable of forming complexes in vivo through hybridization of the respective complementary oligoribonucleotides they are bound to. For example, a first antibody bound to a first oligoribonucleotide through a first chemical linker may be administered to a subject, bind to a cell surface antigen in vivo and subsequently form an antibody complex in vivo with a second antibody bound to a second oligoribonucleotide through a second chemical linker, through complementary base-pairing between the first and the second oligoribonucleotide. The compositions and methods provided herein are, inter alia, useful for diagnostic and therapeutic purposes, for example, the treatment of cancer or autoimmune disease.Type: GrantFiled: October 15, 2021Date of Patent: July 23, 2024Assignee: CITY OF HOPEInventors: John E. Shively, Lin Li, Maciej Kujawski, Piotr Swiderski
-
Patent number: 12018258Abstract: Described in this disclosure are CRISPRi systems and methods, along with the related compositions and kits, that combine modularity, stable genomic integration, and ease of transfer to diverse bacteria by conjugation. CRISPRi compositions, methods, systems and kits described herein allow for genetic dissection of bacteria, facilitating analyses of microbiome function, antibiotic resistances and sensitivities, as well as comprehensive screening for host-microbe interactions. Embodiments of the invention comprise compositions, methods, systems, and kits for CRISPRi-based repression of gene expression in bacteria.Type: GrantFiled: September 4, 2020Date of Patent: June 25, 2024Assignees: CZ Biohub SF, LLC, The Regents of the University of CaliforniaInventors: Jason Peters, Carol Gross, Oren Rosenberg, Neha Prasad
-
Patent number: 12010979Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus and methods of using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR. Methods are also provided for making such non-human animals comprising a humanized TTR locus.Type: GrantFiled: November 22, 2022Date of Patent: June 18, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Meghan Drummond Samuelson, Jeffery Haines, Suzanne Hartford, David Frendewey, Brian Zambrowicz, Andrew J. Murphy
-
Patent number: 11975043Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.Type: GrantFiled: October 13, 2022Date of Patent: May 7, 2024Assignee: Genzyme CorporationInventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
-
Patent number: 11976301Abstract: The present invention provides a method for producing megakaryocytes that have an increased capacity to produce platelets, the method comprising a step of culturing, under conditions that cause the death of cells that do not express a gene that is specifically expressed by megakaryocytes, cells that have the capacity to differentiate into megakaryocytes.Type: GrantFiled: March 22, 2021Date of Patent: May 7, 2024Assignees: Megakaryon Corporation, Kyoto UniversityInventors: Takeaki Dohda, Sachiko Kobayashi, Koji Eto, Hiroshi Endo, Sou Nakamura
-
Patent number: 11939594Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.Type: GrantFiled: March 14, 2018Date of Patent: March 26, 2024Assignee: Seattle Children's HospitalInventors: David J. Rawlings, Richard James, Shaun W. Jackson, Iram Khan, King Hung, Andrew M. Scharenberg
-
Patent number: 11938159Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: GrantFiled: December 23, 2020Date of Patent: March 26, 2024Assignee: AKAMIS BIO LIMITEDInventors: Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
-
Patent number: 11931427Abstract: The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.Type: GrantFiled: October 30, 2020Date of Patent: March 19, 2024Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Josephine Juettner, Dasha Nelidova, Botond Roska
-
Patent number: 11911440Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.Type: GrantFiled: November 10, 2022Date of Patent: February 27, 2024Assignee: Genzyme CorporationInventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
-
Patent number: 11873511Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.Type: GrantFiled: October 19, 2017Date of Patent: January 16, 2024Assignee: CELLECTISInventors: Brian Busser, Philippe Duchateau, Alexandre Juillerat, Laurent Poirot, Julien Valton
-
Patent number: 11866480Abstract: This invention relates to vectors for delivery of human leukocyte antigen G to the eye and/or to cornea explants and methods of using the same for treatment and/or prevention of corneal transplant rejection and other disorders associated with an immune response and/or vascularization.Type: GrantFiled: July 26, 2017Date of Patent: January 9, 2024Assignees: The University of North Carolina at Chapel Hill, North Carolina State UniversityInventors: Matthew Louis Hirsch, Brian Christopher Gilger
-
Patent number: 11859216Abstract: Bacillus agaradhaerens strain WDG185 expresses an inulosucrase that efficiently synthesizes a broad range of IOS with a GF range of GF3-GF30. The isolated and/or purified inulosucrase, recombinantly engineered variants thereof, active fragments thereof, synthetic nucleic acids encoding the inulosucrase, its variants, or its active fragments, host cells comprising the synthetic nucleic acids, and compositions comprising the inulosucrase are provided. Methods of using the compositions include the manufacture of inulooligosaccharides.Type: GrantFiled: September 17, 2020Date of Patent: January 2, 2024Assignee: Danisco US Inc.Inventors: Slavko Kralj, Marc Kolkman, Chris Leeflang, Johannes G. De Nobel, Arjen Hoekstra, Veli Alkan
-
Patent number: 11851676Abstract: Human Neural precursor cells (hNPCs)/cell lines derived from human pluripotent stem cells have been stably transduced with inducible lentiviral constructs for knockdown of STIM1 thereby changing their gene expression. The said Human Neural precursor cells (hNPCs)/cell lines has selectively inducible knockdown of STIM1 via stable transduction of lentiviral shRNA vector followed by Doxycycline treatment. Human Neural precursor cells (hNPCs)/cell lines with stable knockdown STIM1 exhibits attenuated SOCE with downregulation of genes associated with cell proliferation and upregulation of genes for neural differentiation.Type: GrantFiled: April 17, 2019Date of Patent: December 26, 2023Assignee: NATIONAL CENTRE FOR BIOLOGICAL SCIENCESInventors: Renjitha Gopurappilly, Gaiti Hasan, Bipan Kumar Deb
-
Patent number: 11813317Abstract: Provided is a method for preventing or treating a metabolic disorder, including administering to a subject a therapeutically effective amount of TRABID protein or a functionally related variant thereof, or a nucleic acid encoding TRABID protein or a functionally related variant thereof. Also provided is a method for reducing fat accumulation through TRABID-induced deubiquitination to promote autophagy activity and lipid metabolism.Type: GrantFiled: December 2, 2021Date of Patent: November 14, 2023Assignees: Academia Sinica, National Yang Ming Chiao Tung UniversityInventors: Ruey-Hwa Chen, Yu-Hsuan Chen, Tzu-Yu Huang, Wen-Hsin Li, Ting-Fen Tsai, Zhao-Qing Shen
-
Patent number: 11802272Abstract: Methods of, treatments using, and devices for restoring the regenerative capability for mesenchymal stem cells and isolating and expanding a small subpopulation of less defective mesenchymal stem cells from the bone marrow stromal cells of people with decreased quality and/or quantity of mesenchymal stem cells, such as elderly people.Type: GrantFiled: November 4, 2016Date of Patent: October 31, 2023Assignee: The Board of Regents of The University of Texas SystemInventors: Travis Block, Milos Marinkovic, Xiao-dong Chen
-
Patent number: 11781142Abstract: Aspects of the disclosure relate to methods and compositions for treating pancreatic cancer (e.g., islet cell tumors). In some aspects, adeno-associated virus (AAV) may be used to deliver an interfering RNA that targets thymidylate synthase (TS).Type: GrantFiled: November 3, 2017Date of Patent: October 10, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Maria Zajac-Kaye, Kyungah Maeng
-
Patent number: 11773368Abstract: A problem of this invention it to provide a method for differentiate a primordial germ cell into a functional GV stage oocyte by in vitro culture. This invention relates to a method for differentiating a primordial germ cell into a functional GV stage oocyte by in vitro culture, comprising: (a) a step of producing a secondary follicle by culturing the primordial germ cell and supporting cells adjacent to the primordial germ cells under conditions that eliminate the effects of estrogen or a factor having a similar function to estrogen; (b) a step of partially dissociating cells between a granulosa cell layer and a thecal cell layer, wherein an oocyte, the granulosa cell layer, and the thecal cell layer constitute the produced secondary follicle; and (c) a step of differentiating the oocyte into a functional GV stage oocyte by culturing the oocyte, the granulosa cell layer, and the thecal cell layer that constitute the secondary follicle in a medium containing a high-molecular-weight compound.Type: GrantFiled: September 16, 2016Date of Patent: October 3, 2023Assignees: NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, TOKYO UNIVERSITY OF AGRICULTURE EDUCATIONAL CORPORATEDInventors: Yayoi Obata, Yuji Hirao, Katsuhiko Hayashi